Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Complex product composition generates risks for generic substitution also with dosage forms for intravenous administration.

Rossi A, Buttini F, Colombo P, Mor M, Pala D, Bortolotti F, Colombo G.

Int J Pharm. 2013 Jul 15;451(1-2):50-6. doi: 10.1016/j.ijpharm.2013.04.064. Epub 2013 Apr 27.

PMID:
23628401
2.

Composition specification of teicoplanin based on its estimated relative bioavailability.

Boix-Montañes A, Garcia-Arieta A.

Drug Dev Ind Pharm. 2015 Feb;41(2):218-23. doi: 10.3109/03639045.2013.858733. Epub 2014 Feb 10.

PMID:
24506456
3.

About the equivalence between different batches of a glycopeptide drug.

Boix-Montañes A, Garcia-Arieta A.

Pharm Dev Technol. 2016 Aug;21(5):642-5. doi: 10.3109/10837450.2015.1035726. Epub 2015 Apr 17.

PMID:
25886080
4.

Actinoplanes teichomyceticus ATCC 31121 as a cell factory for producing teicoplanin.

Taurino C, Frattini L, Marcone GL, Gastaldo L, Marinelli F.

Microb Cell Fact. 2011 Oct 18;10:82. doi: 10.1186/1475-2859-10-82.

5.

Statistical and regulatory considerations in assessments of interchangeability of biological drug products.

Tóthfalusi L, Endrényi L, Chow SC.

Eur J Health Econ. 2014 May;15 Suppl 1:S5-11. doi: 10.1007/s10198-014-0589-1. Epub 2014 May 16.

6.

Isolation and structure determination of a novel complex of the teicoplanin family.

Quarta C, Borghi A, Zerilli LF, De Pietro MT, Ferrari P, Trani A, Lancini GC.

J Antibiot (Tokyo). 1996 Jul;49(7):644-50.

7.

Multicomponent antibiotic substances produced by fermentation: implications for regulatory authorities, critically ill patients and generics.

Brink AJ, Richards GA, Colombo G, Bortolotti F, Colombo P, Jehl F.

Int J Antimicrob Agents. 2014 Jan;43(1):1-6. doi: 10.1016/j.ijantimicag.2013.06.013. Epub 2013 Aug 3. Review.

PMID:
23920094
8.

Glycerol affects the acyl moieties of teicoplanin components produced by Actinoplanes teichomyceticus MSl2210.

Park HR, Lee JC, Hwang JH, Park DJ, Kim CJ.

Microbiol Res. 2009;164(5):588-92. Epub 2007 Jul 30.

9.

Generic low-molecular-weight heparins: some practical considerations.

Fareed J, Leong WL, Hoppensteadt DA, Jeske WP, Walenga J, Wahi R, Bick RL.

Semin Thromb Hemost. 2004 Dec;30(6):703-13. Review.

PMID:
15630677
10.

Production of teicoplanin by valine analogue-resistant mutant strains of Actinoplanes teichomyceticus.

Jin ZH, Wang MR, Cen PL.

Appl Microbiol Biotechnol. 2002 Jan;58(1):63-6.

PMID:
11833531
11.

[Comments on generic antibiotics].

Levêque D, Gourieux B.

Med Mal Infect. 2013 Jan;43(1):35-6. doi: 10.1016/j.medmal.2012.11.003. Epub 2012 Dec 31. Review. French. No abstract available.

PMID:
23287656
12.

Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics.

Zuluaga AF, Agudelo M, Rodriguez CA, Vesga O.

BMC Clin Pharmacol. 2009 Jan 16;9:1. doi: 10.1186/1472-6904-9-1.

13.

Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.

Maddineni J, Walenga JM, Jeske WP, Hoppensteadt DA, Fareed J, Wahi R, Bick RL.

Clin Appl Thromb Hemost. 2006 Jul;12(3):267-76.

PMID:
16959680
14.

Biosynthesis, biotechnological production, and application of teicoplanin: current state and perspectives.

Jung HM, Jeya M, Kim SY, Moon HJ, Kumar Singh R, Zhang YW, Lee JK.

Appl Microbiol Biotechnol. 2009 Sep;84(3):417-28. doi: 10.1007/s00253-009-2107-4. Epub 2009 Jul 16. Review.

PMID:
19609520
15.

Antibacterial effects of brand-name teicoplanin and generic products against clinical isolates of methicillin-resistant Staphylococcus aureus.

Fujimura S, Fuse K, Takane H, Nakano Y, Gomi K, Kikuchi T, Watanabe A.

J Infect Chemother. 2011 Feb;17(1):30-3. doi: 10.1007/s10156-010-0094-0. Epub 2010 Jul 28.

PMID:
20665064
16.

Exploring quality and its potential effects of multi-components antibiotic: consistency evaluation between matrix components ratio and microbiological potency of teicoplanin.

Chang Y, Wang N, Yao SC, Hu CQ.

J Antibiot (Tokyo). 2013 Nov;66(11):641-6. doi: 10.1038/ja.2013.66. Epub 2013 Jul 3.

PMID:
23820615
17.

Valine influences production and complex composition of glycopeptide antibiotic A40926 in fermentations of Nonomuraea sp. ATCC 39727.

Beltrametti F, Jovetic S, Feroggio M, Gastaldo L, Selva E, Marinelli F.

J Antibiot (Tokyo). 2004 Jan;57(1):37-44.

18.

Non-inpatient use of teicoplanin.

Nathwani D.

Int J Clin Pract. 1998 Nov-Dec;52(8):577-81. Review.

PMID:
10622058
19.

Generic antibiotic drugs: is effectiveness guaranteed?

Gauzit R, Lakdhari M.

Med Mal Infect. 2012 Apr;42(4):141-8. doi: 10.1016/j.medmal.2011.10.013. Epub 2012 Apr 4. Review.

PMID:
22480963
20.

Biodegradable implantable teicoplanin beads for the treatment of bone infections.

Yenice I, Caliş S, Kaş H, Ozalp M, Ekizoğlu M, Hincal A.

Int J Pharm. 2002 Aug 21;242(1-2):271-5.

PMID:
12176262

Supplemental Content

Support Center